Wall Street's Top Analyst Calls: SpaceX Initiated, Salesforce Upgraded
Money

Wall Street's Top Analyst Calls: SpaceX Initiated, Salesforce Upgraded

authorBy JL Collins
DateJun 18, 2026
Read Time4 min

In the dynamic world of financial markets, the latest analyst assessments are crucial for investors. This comprehensive report summarizes the most impactful research calls from leading Wall Street firms, detailing significant upgrades, downgrades, and new coverage initiations that are shaping investment strategies and market perceptions today.

Wall Street Shakes Up Stock Valuations with Key Analyst Moves

On Thursday, June 18, 2026, a flurry of significant analyst activities reverberated across Wall Street, influencing major players in various sectors. The Fly compiled these pivotal research calls, offering a snapshot of market sentiment.

Among the top upgrades, Monness Crespi elevated Salesforce (CRM) from Neutral to Buy, setting a price target of $200. This positive revision stemmed from the firm's belief in Salesforce's "compelling" valuation, its advancements in aiding customers with agentic enterprise transformations, an appealing margin profile, robust cash flow generation, and a generous stock repurchase program. Similarly, Barclays lifted Enphase Energy (ENPH) from Underweight to Equal Weight, increasing its price target from $30 to $51, citing the company's emerging solid-state transformer data center opportunities. DA Davidson upgraded Nice (NICE) to Buy with an unchanged $110 price target, following insightful discussions at the company's annual user event that indicated investors' views on AI disruption were more cynical than the reality within contact centers. Rothschild & Co Redburn moved Verisk Analytics (VRSK) to Neutral from Sell, maintaining a $185 price target, after the termination of the AccuLynx acquisition and the company navigating challenging cyclical quarters with minimal disruption. Barclays also upgraded uniQure (QURE) to Overweight from Equal Weight, raising its price target from $25 to $65, due to the highly anticipated plans to file a Biologics License Application (BLA) for Huntington's in the third quarter.

However, not all news was favorable. Stifel downgraded Intuit (INTU) from Buy to Hold, slashing its price target from $375 to $275. The firm anticipates management to lower near-to-medium-term growth targets for both TurboTax and GBS during the fourth-quarter results or the September Analyst Day. Scotiabank downgraded Prologis (PLD) to Sector Perform from Outperform, with its price target reduced from $154 to $146, arguing that Prologis' valuation premium to the U.S. REIT sector is difficult to justify given its more modest funds from operations growth. Rothschild & Co Redburn downgraded FactSet (FDS) to Sell from Neutral, lowering its price target from $291 to $215, as the firm notes the erosion of the terminal's dominance due to unbundled data consumption impacting FactSet's pricing power. H.C. Wainwright downgraded Traws Pharma (TRAW) to Neutral from Buy, cutting the price target from $8 to $1, after the company deferred its Phase 2a human influenza challenge study due to a negative review from the UK's Medicines and Healthcare Products Regulatory Agency. Morgan Stanley downgraded Curbline Properties (CURB) to Equal Weight from Overweight, with a $30 price target, indicating that the prior thesis had played out and the focus was shifting to the ability to sustain accretive acquisition-led growth without capital rate compression.

New coverage initiations also made headlines. Arete initiated coverage of SpaceX (SPCX) with a Buy rating and an impressive Street-high price target of $401. The firm highlighted SpaceX's adeptness at breaking down complex engineering challenges into manageable tasks while developing hardware and software for space, connectivity, and AI. Citi resumed coverage of Costco (COST) with a Neutral rating and a $1,020 price target, acknowledging Costco's long-term market share gains but deeming its risk/reward balanced at current share levels. Goldman Sachs initiated coverage of Talen Energy (TLN) with a Buy rating and a $499 price target, foreseeing a 29% total return, attributing this to Talen's 17-year power purchase agreement with Amazon Web Services (AMZN) which transformed the company into a hybrid contracted independent power producer. Goldman Sachs also initiated coverage of Constellation Energy (CEG) with a Neutral rating and a $305 price target, implying a 17% total return, recognizing Constellation as a high-quality independent power producer despite its shares trading at a significant premium. Finally, Texas Capital initiated coverage of Andersons (ANDE) with a Buy rating and a $110 price target, citing the company's differentiated exposure to the U.S. ethanol and renewable feedstocks industries through its vertically integrated business model.

The latest wave of analyst actions underscores the ongoing evaluation of market conditions, technological advancements, and corporate strategies. For investors, these calls offer critical insights into potential shifts in stock performance and sector outlooks, guiding them in making informed decisions amidst evolving market dynamics.

More Articles
Money
Giverny Capital Exits AMETEK Due to Overvaluation Concerns
Giverny Capital Asset Management divested its holdings in AMETEK, Inc. in February, citing an elevated price-to-earnings (PE) multiple that no longer aligned with the company's long-term earnings growth and return on equity. Despite a history of solid performance from AMETEK, the investment firm concluded that its valuation had become stretched, prompting the sale to optimize its portfolio for better-valued opportunities, particularly in the AI sector.
By Vicki RobinJun 18, 2026
Money
Ahold Delhaize Settles Prescription Pricing Allegations for $40 Million
Ahold Delhaize USA has agreed to a $40 million settlement over allegations of inflating prescription drug pricing data submitted to federal healthcare programs. The Department of Justice stated that these inflated reports led government programs like Medicare Part D, Medicaid, and Tricare to overpay pharmacies. The settlement emphasizes the importance of accurate pricing information for taxpayer-funded healthcare.
By Natalie PaceJun 18, 2026
Money
Evernorth CEO Endorses XRP's Potential to Outshine PayPal in Digital Finance
Evernorth CEO Ashish Birla asserts that blockchain technology is no longer a futuristic concept but a present-day solution to real financial challenges. He emphasizes tokenization as the next major shift, transforming assets into accessible, programmable, and efficient forms on blockchain networks. Birla highlights XRP's prime position to lead this transformation due to its technology and institutional support.
By Bola SokunbiJun 18, 2026
Money
Thistle Resources Progresses Towards Full Ownership of Brunswick Antimony Project with Key Payment
Thistle Resources has made its second anniversary payment for the Brunswick antimony project in New Brunswick, moving closer to full ownership. This strategic move involved a cash payment and the issuance of common shares, highlighting the company's commitment to developing this significant mineral property and creating long-term value for its shareholders through systematic exploration.
By JL CollinsJun 18, 2026
Money
Ingersoll Rand Inc. Shows Signs of Recovery and Market Optimism
Turtle Creek Asset Management's Q1 2026 report highlights Ingersoll Rand Inc.'s (IR) strong recovery, with a book-to-bill ratio above one for the first time since 2022 and positive organic order growth. Despite market volatility and the firm's fund returning -4.8% for the quarter, Ingersoll Rand's optimistic outlook and resilience in an extended industrial recession are noted. The company, a provider of industrial machinery and critical technologies, closed at $77.07 per share with a $30.16 billion market cap.
By Ramit SethiJun 18, 2026